MALDI-TOF MS. Learning Objectives. MALDI-TOF MS: a new tool to rapidly assess antibiotic susceptibility. After this presentation, you should

Similar documents
Applications for MALDI-TOF MS in Clinical Microbiology. MALDI-TOF is not a Cocktail. The Ideal Identification System 9/10/2012

BD Phoenix Automated Microbiology System

Antimicrobial Resistance and Human Health

Antibiotic resistance does it matter in paediatric clinical practice? Jette Bangsborg Department of Clinical Microbiology Herlev Hospital

Disc Diffusion Susceptibility Methods

TEST METHOD VERIFICATION AND VALIDATION

HUSRES Annual Report 2010 Martti Vaara

[ Care and Use Manual ]

Management of Extended Spectrum Beta- Lactamase (ESBL) Producing Enterobacteriaceae in health care settings

The 14th EURL-AR Proficiency Test - enterococci, staphylococci and E. coli Lina Cavaco Susanne Karlsmose Rene S. Hendriksen Frank M.

How To Treat Mrsa From A Dead Body

Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae

HUSRES Annual Report 2008 Martti Vaara.

The Stewardship Geek Squad. Disclosure. Objectives (Pharmacist Track) Calling the Stewardship Geek Squad: Integrating Information Technology &

Evaluation of MALDI-TOF MS in the microbiology laboratory

MagExtractor -Genome-

AB SCIEX TOF/TOF 4800 PLUS SYSTEM. Cost effective flexibility for your core needs

Lab 10: Bacterial Transformation, part 2, DNA plasmid preps, Determining DNA Concentration and Purity

How To Treat Mrsa In Finnish

Bruker ToxScreener TM. Innovation with Integrity. A Comprehensive Screening Solution for Forensic Toxicology UHR-TOF MS

Originally published as:

HUSRES Annual Report 2015

Introduction. Introduction. Why do we need microbiological diagnostics of udder infections? Microbiological diagnostics How is it done?

Aiping Lu. Key Laboratory of System Biology Chinese Academic Society

Bio and Polymer Analytics. RD Instrumental Analytical Chemistry. Organic Trace Analytics. RD Environmental & Process Analytics

Laboratory Exercise # 11: Differentiation of the Species Staphylococcus and Streptococcus

Covalent Conjugation to Cytodiagnostics Carboxylated Gold Nanoparticles Tech Note #105

The role of MALDI-TOF in Clinical Microbiology, Including the Rapid Identification of Isolates from Positive Blood Cultures

Standard Mixture. TOF/TOF Calibration Mixture. Calibration Mixture 1 (Cal Mix 1, 1:10) Calibration Mixture 1 (Cal Mix 1, 1:100)

Twincore - Zentrum für Experimentelle und Klinische Infektionsforschung Institut für Molekulare Bakteriologie

Test Method for the Continuous Reduction of Bacterial Contamination on Copper Alloy Surfaces

Urinary Tract Infections

Streptococcus pneumoniae IgG AB (13 Serotypes), MAID... 7

Hasan Ağın 1, Fahri Yüce Ayhan 2, Zeynep Gülay 3, Gamze Gülfidan 2, Nevbahar Yaşar 4, Bayrı Eraç 3, İlker Devrim 5

HOW TO WRITE AN UNKNOWN LAB REPORT IN MICROBIOLOGY

FACULTY OF MEDICAL SCIENCE

Prevalence of Metallo-β-lactamases Encoding Genes Among Pseudomonas

ANNUAL REPORT ON STAPHYLOCOCCUS AUREUS BACTERAEMIA CASES IN DENMARK 2009 (part I)

Imipenem and meropenem resistance amongst ESBL producing Escherichia coli and Klebsiella pneumoniae clinical isolates

Nosocomial Antibiotic Resistance in Multiple Gram-Negative Species: Experience at One Hospital with Squeezing the Resistance Balloon at Multiple Sites

TransformAid Bacterial Transformation Kit

ANNUAL REPORT ON STAPHYLOCOCCUS AUREUS BACTERAEMIA CASES IN DENMARK 2008 (part I)

MultiQuant Software 2.0 for Targeted Protein / Peptide Quantification

Received 22 March 2006/Returned for modification 2 May 2006/Accepted 14 September 2006

UTILIZATION of PLASMA ACTIVATED WATER in Biotechnology, Pharmacology and Medicine. JSC TECHNOSYSTEM-ECO Moscow, Russia April, 2009

Urinary tract infections caused by extended spectrum β-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae

Beta-Lactamase Encoding Gene Among Extended Spectrum B-Lactamase Positive Wound Isolates of Pseudomonas

Transformation of the bacterium E. coli. using a gene for Green Fluorescent Protein

The Antimicrobial Susceptibility Testing Device Manufacturer: Development Process, Timelines, and Challenges

Application Note # LCMS-81 Introducing New Proteomics Acquisiton Strategies with the compact Towards the Universal Proteomics Acquisition Method

`TORAY TEXTILES EUROPE

Labor im Zentrifugenröhrchen zur dezentralen patientennahen Diagnostik

MIBIE Summer School Molecular diagnostics of UTI & STI by using PCR, DHPLC and NGS

Prevalence of Klebsiella pneumoniae Encoding Genes for Ctx-M-1, Tem-1 and Shv-1 Extended-Spectrum Beta Lactamases (ESBL) Enzymes in Clinical Specimens

Ozone Inactivation Kinetics of Multiple Antibiotic Resistant Strains of Bacteria in Water.

Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting -

MEDICAL MICROBIOLOGY 603 OR POPULATION HEALTH SCIENCES 603 CLINICAL AND PUBLIC HEALTH MICROBIOLOGY January 18-May 6, 2011

ProteinScape. Innovation with Integrity. Proteomics Data Analysis & Management. Mass Spectrometry

CARE. Price List for CARE Products. Version CARE in JPY as of Jan, 2015 Prices are subject to change without prior notice. Innovation with Integrity

Appendix 5 Overview of requirements in English

Open Access Article pissn eissn

SEA-HLM-415 Distribution: General. Establishment of national laboratory-based surveillance of antimicrobial resistance

Effects of Intelligent Data Acquisition and Fast Laser Speed on Analysis of Complex Protein Digests

Transformation Protocol

13C NMR Spectroscopy

Helsingin ja Uudenmaan alueen herkkyystilastoja

Microbiology BIOL 275 DILUTIONS

Transfection reagent for visualizing lipofection with DNA. For ordering information, MSDS, publications and application notes see

m/z

IDENTIFICATION OF OTHER UNKNOWN BACTERIAL SPECIES: OU

Biological Sciences Initiative

for mass spectrometry calibration tools Thermo Scientific Pierce Controls and Standards for Mass Spectrometry

Urinary Tract Infections

Lipid analysis by multiple "omic" mass spectrometry platforms Where we ve been, where we are, and where we re going

Laboration 1. Identifiering av proteiner med Mass Spektrometri. Klinisk Kemisk Diagnostik

BD Modified CNA Agar BD Modified CNA Agar with Crystal Violet

Chapter 2: The Chemical Context of Life

URINE CULTURES GENERAL PROCEDURE

Enumerating Chromogenic Agar Plates Using the Color QCOUNT Automated Colony Counter

Direct Testing Systems and Serology

Welcome to Implementing Inquirybased Microbial Project. Veronica Ardi, PhD

Overview. Introduction. AB SCIEX MPX -2 High Throughput TripleTOF 4600 LC/MS/MS System

Simultaneous Metabolite Identification and Quantitation with UV Data Integration Using LightSight Software Version 2.2

Simultaneous qualitative and quantitative analysis using the Agilent 6540 Accurate-Mass Q-TOF

The 11 th EURL-AR Proficiency Testing Salmonella and Campylobacter Susanne Karlsmose Lina M. Cavaco Rene S. Hendriksen Frank M.

GCSE BITESIZE Examinations

Version 12 May BSAC Methods for Antimicrobial Susceptibility Testing. All enquiries to: Mandy Wootton.

Bacillus Subtilis Expression Vectors. Product Information and Instructions November 2005

Global Spread of Carbapenemase- Producing Klebsiella pneumoniae

Proteomics in Practice

Introduction to Proteomics 1.0

Transcription:

MALDI-TOF MS: a new tool to rapidly assess antibiotic susceptibility Sören Schubert, MD Max von Pettenkofer-Institut Ludwig-Maximilians-University (LMU) Munich, Germany Learning Objectives After this presentation, you should know the principles of MALDI-TOF MS and its application in identification of microorganisms be able to identify and to trace the development of MALDI-TOF MS for the -lactamase activity testing of bacteria record and compare facts about different approaches using MALDI-TOF MS for comprehensive antibiotic resistance testing be able to identify the pros and cons of using MALDI- TOF MS for resistance testing in diagnostic laboratory and will retrace possible future perspectives MALDI-TOF MS MALDI Biotyper Bruker Daltonics Vitek MS biomérieux 1

MALDI-TOF: principle Matrix Assisted Laser Desorption/Ionization, Time Of Flight MALDI TOF Identification of bacteria and fungi Intens. [a.u.] 5 4364.6 4 538.64 6254.64 596.1 6315.49 3 2 641.9 7157.65 7273.87 1 787.62 8368.99 4 45 5 55 6 65 7 75 8 m/z E. coli MALDI-TOF MS bacteria identification Workflow 2

Identification Antibiotic resistance testing (AST) Disc Diff. Walkaway Vitek 2 Phoenix Time to result 12 24 h 12 48 h 7 18 h 8 18 h MALDI-TOF MS 1. Direct detection of resistance factors 3

MRSA detection by MALDI-TOF MS? MRSA MALDI TOF detection of MRSA 4

Wolters et al., 211 MALDI-TOF for detection of antibiotic resistance -lactamases (ESBL) carbapenemases Problem 5

SHV-1 SHV-2 SHV-3 SHV-178 TEM-1 TEM-2 TEM-3 TEM-213 CTX-M-1 CTX-M-2 CTX-M-3 CTX-M-75 OXA-1 OXA-2 OXA-3 OXA-161 CMY-1 CMY-2 CMY-3 CMY-23 IMP-1 IMP-2 IMP-3 IMP-23 > 7 -lactamase - subtypes Conclusion 1: Direct detection of resistance factors Detection of clonal groups No reliable resistance identification -lactamases, PBP2a, Van A Van B MALDI-TOF MS 1. Direct detection of resistance factors (e.g. PBP2a) 2. β-lactamase activity test 6

-lactamase activity +H 2 O + 18 Da - 44 Da A B C Ampicillin + ESBL-E. coli Ampicillin + -Lact.-neg. E. coli C A B Sparbier et al., 212 Procedure 1 colony of fresh o/n culture 1 µl antibiotic solution (e.g..5 µg/ml CTX) 1-2 h incubation, 37 C Spin down bacteria Supernatant on MALDI-target plate Mass range 1 1 Da Calibration with suitable molecules 7

Cefotaxime (CTX) Intens. [a.u.] x1 4 5 4 3 2 1 396. 414.1 456.1 A CTX + ESBL- neg. E. coli Intens. [a.u.] x1 4.8.6.4.2 369.9 414. 445. 46.9 B CTX + ESBL-pos. E. coli Intens. [a.u.]. x1 4 C 1.5 1..5. 36 38 4 42 44 46 48 m/z 396.1 414.1 456.1 CTX / CLAV + ESBL-pos. E. coli Σ peak-intensity hydrolysed log Σ peak-intensity non-hydrolysed.5 mg/ml CAZ in 1 mm NH 4 -hydrogen carbonate 2 h incubation 15 µl sup plus 5 µl.5 ng/µl reserpine 1.5 µl spotted -lactamaseactivity No cleavage spontaneous hydrolysis 8

Identification -lactamase activity E. coli directly from positve blood cultures ampicillin 1 Ampicillin MIC >8.5 logrq Ampicillin MIC 8 -.5 4 MIC>256 5 MIC 4 9 MIC 8 1 MIC >256 11 MIC >256 16 MIC >256 18 MIC >256 2 MIC 3 21 MIC 4 22 MIC 3 25 MIC 4 3 MIC 6 31 MIC 4 37 MIC 6 39 MIC 2 4 MIC >256 41 MIC 3 42 MIC >256 45 MIC >256 46 MIC 4 47 MIC>256 51 MIC>256 52 MIC 4 54 MIC >256 55 MIC >256 56 MIC >256 57 MIC >256 6 MIC >256 61 MIC >256 62 MIC 4 66 MIC >256 67 MIC >256 69 MIC 4 72 MIC >256 73 MIC >256 74 MIC >256 76 MIC >256 81 MIC >256 82 MIC 6 84 MIC >256 85 MIC 3 86 MIC >256 87 MIC 8 9 MIC 2 91 MIC >256 92 MIC >256/4 93 MIC 1,5 94 MIC >256 E. coli ATCC 25922 Jung et al., 214 Conclusion 2: MALDI-TOF -lactamase activity test Rapid test 1.5 3 h Automated analysis Directly from positive blood cultures Restricted to certain antibiotic resistances -lactamases, e.g. ESBL, carbapenemases 9

MALDI-TOF MS 1. Direct detection of resistance factors (e.g. PBP2a) -lactamase activity test 3. Antibiotic susceptibility test - phenotypic assays MBT-RESIST Phenotypic Susceptibility Testing (MBT-RESIST) 13 C 6 15 N 2 -L-Lysin 8Da 8Da For all growing bacteria applicable Susceptible: No integration Resistant: Integration Susceptibility testing using stable isotopes normal Lys Control 1 heavy Lys + antibiotic Susceptible Resistant heavy Lys Control 2 October 22, 215 3 1

5 51 52 53 54 55 56 57 58 m/z S. aureus mass spectra gel view MSSA OXA - susceptible strain MRSA OXA - resistant strain normal normal heavy + Oxa heavy + Oxa heavy heavy October 22, 215 31 MRSA P. aeruginosa MBT MS-RESIST / P. aeruginosa (Tobramycin- susceptible) Intens. [a.u.] 6 5 5213.353 5739.928 125_N :B8 MS, BaselineSubtracted, Smoothed 4 3 2 5116.874 normal 1 6 5212.952 12_H_6 :A1 MS, BaselineSubtracted, Smoothed 5 4 3 2 1 5116.441 5739.242 heavy + TOB Intens. [a.u.] 6 12_H :A7 MS, BaselineSubtracted, Smoothed 4 521.891 5213.753 5117.392 5244.916 574.349 5795.447 heavy 2 Jung et al., EJCMID 213 October 22, 215 33 11

MS-RESIST/ P. aeruginosa (Tobramycin-resistant) Intens. [a.u.] 5 4 65.312 425_N :G1 MS, BaselineSubtracted, Smoothed 6679.371 3 2 574.567 6351.691 normal 1 6 6113.22 663.988 42_H_6 :G1 MS, BaselineSubtracted, Smoothed 5 4 3 2 1 649.92 6351.31 5739.994 6113.19 639.383 5796.772 6678.694 6717.281 heavy + TOB 1.25 Intens. [a.u.]x1 4 65.252 42_H :F11 MS, BaselineSubtracted, Smoothed 6679.317 1..75.5 574.398 6113.323 5796.23 6351.65 6718.17 639.951 heavy.25. 56 58 6 62 64 66 m/z Jung et al., EJCMID 213 October 22, 215 34 ciprofloxacin Pseudomonas aeruginosa meropenem tobramycin Jung et al., 214 MALDI-TOF MS 1. Direct detection of resistance factors (e.g. PBP2a) -lactamase activity test 3. Antibiotic susceptibility test - phenotypic assays MBT-RESIST MBT-ASTRA 12

3. Antibiotic susceptibility testing by phenotypic assays Phenotypic assay without isotopes? MALDI-TOF MS as a quantitative growth monitor MBT-ASTRA BHI McF.5 Incubation 37 C Species dependent time Antibiotic Cell lysis Lysis reagent with internal standard Target preparation Acquisition of MS profile spectra spectra view Klebsiella pneumoniae Standard [M+ H] 2+ Standard [M+ H] + Standard [M+ H] 2+ Standard [M+ H] + BHI + Meropenem 8 µg/ml susceptible BHI only Meropenem resistant Lange et al., J Clin Microbiol. 214 13

Conclusion (1) Direct detection of resistance factors Detection of clonal groups May help to identify distinct clonally distributed resistance factors False positive and negative results possible! (yet) no direct detection of -lactamases, PBP2a, Van A/B, Conclusion (2) -lactamase activity test Rapid test 1.5 3 h Automated analysis Directly from positive blood cultures Restricted to certain resistances -lactamases All -lactamases detectable? Conclusion (3) Phenotypic resistance test (MBT-RESIST / MBT-ASTRA) Rapid tests 2 3 h Automated analysis available Stable Isotopes: A rather complex workflow kits and cards are needed All bug-drug combinations analyzable? 14

MALDI-TOF MS for antibiotic resistance testing Pro Reduction of time to result: 12 h 2.5 h Phenotypic assay irrespective of underlying molecular mechanism High-throughput feasible Low costs of consumables Cons Initial culture necessary plus 12 24 h High costs of MALDIhardware (Yet) no determination of MIC values (Yet) no test kits available hands on time is high Max von Pettenkofer-Institut Jette Jung Theresa Eberl Christina Popp Julia Walker Christina Hamacher Lukas Schmidt Birgit Gross Andreas Wieser ForBIMed FöFoLe 15